Enrolling by invitationNo phase
Follows children with juvenile inflammatory rheumatism over time
Follows children with juvenile arthritis to study treatment safety and benefit.
Plain-language title generated from the registry record
Registry title: Juvenile Inflammatory Rheumatism (JIR) Cohorte
Key facts
- Where
- Aarau, Basel, Bellinzona, Chur, Lausanne, Lucerne, Lugano, Sankt Gallen, Valens, Winterthur, and Zurich, SwitzerlandSee the 13 sites
Where in Switzerland
- Kantonsspital AarauAarau, SwitzerlandNo longer taking part
- Kinderspital BaselBasel, SwitzerlandNo longer taking part
- Universitäts-Augenklinik BaselBasel, SwitzerlandNo longer taking part
- Ospedale Regionale di Bellinzona e ValliBellinzona, SwitzerlandNo longer taking part
- Kantonspital GraubundenChur, SwitzerlandNo longer taking part
- CHUVLausanne, SwitzerlandNo longer taking part
- Hôpital OphtalmiqueLausanne, SwitzerlandNo longer taking part
- Kinderspital LuzernLucerne, SwitzerlandNo longer taking part
- Ospedale Regionale di LuganoLugano, SwitzerlandNo longer taking part
- Ostschweizer Kinderspital St-GallenSankt Gallen, SwitzerlandNo longer taking part
- Klinik für Rheumatologie und internistische RehabilitationValens, SwitzerlandNo longer taking part
- Kantonspital WinterthurWinterthur, SwitzerlandNo longer taking part
- Kinderspital ZürichZurich, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Michaël Hofer
- Trial code
- NCT02377245
- Record updated
- 15 June 2023
- Original description
The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.Read full original descriptionShow less
Setting up a Pediatric Cohort for Inflammatory Rheumatic Diseases
The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.
Inclusion: Patients with juvenile inflammatory diseases; Age at onset up to 18 years old; Consent according national codes of ethics and current laws.
Exclusion: Non-consent from patients and/or legal representative.